Study Stopped
Unable to continue due to low enrollment and lack of resources.
Alexa, What is Eliquis and Xarelto?
1 other identifier
interventional
36
1 country
1
Brief Summary
The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2021
CompletedFirst Posted
Study publicly available on registry
March 10, 2021
CompletedStudy Start
First participant enrolled
May 21, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2021
CompletedMarch 21, 2022
March 1, 2022
1 month
March 8, 2021
March 7, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
% Change in pre- and post test scores
Effectiveness of Alexa based education by assessing understanding of Eliquis and Xarelto pre and post Alexa education
Within 72 hours of education
Secondary Outcomes (3)
7-day post-education retention rate
1 week post discharge
Nursing satisfaction
72 hours
Patient satisfaction
72 hours
Study Arms (2)
Standard of care
NO INTERVENTIONPatient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
Alexa Education
ACTIVE COMPARATORPatient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.
Interventions
Amazon Alexa based voice recording of medication education material
Eligibility Criteria
You may qualify if:
- years of age or older
- Have been prescribed either apixaban or rivaroxaban during their inpatient stay
- Consent to participating in the study
- Providing direct patient care in select general medicine and orthopedic surgical units
- Consent to participating in the study
You may not qualify if:
- Patients will be excluded if they have documented altered mental status, do not speak English, or are being prescribed rivaroxaban or apixaban on discharge only.
- Nurses will be excluded if not providing direct patient care in select general medicine and orthopedic surgical units
- Nurses declining participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Pharmacy Manager
Study Record Dates
First Submitted
March 8, 2021
First Posted
March 10, 2021
Study Start
May 21, 2021
Primary Completion
June 30, 2021
Study Completion
October 31, 2021
Last Updated
March 21, 2022
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share